Redsense gets US nod for needle dislodgement alarm:
This article was originally published in Clinica
Executive Summary
Swedish firm Redsense Medical has received 510(k) clearance from the US FDA for its alarm for venous needle dislodgement. The device, for use in haemodialysis patients, can detect as little as 1mm of blood that is released after dislodgement. The product, called Redsense, consists of two parts: a sensor patch and an alarm unit. In the event of bleeding, inner layers of the patch smear blood over the optical sensor, which triggers the alarm. Over 200 million dialysis treatments are performed every year, a number set to increase with the world's ageing population, claimed the Halmstad company. Serious incidents due to needle dislodgment during haemodialysis are estimated to be in the thousands, said Redsense.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.